Int. Journal of Clinical Pharmacology and Therapeutics, Volume 64 (2026) - December (646 - 657)

Baloxavir marboxil versus oseltamivir phosphate: Efficacy, safety, and economics in patients with influenza

Yongli Gu1, Daoli Jiang2, 3
1 Department of Pharmacy, the First People’s Hospital of Lianyungang, Lianyungang Jiangsu, 2 Department of Pharmacy, the Affiliated Hospital of Xuzhou Medical University, and 3 Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou Jiangsu, China

Add to Cart  

 

DOI 10.5414/CP204995

Abstract

Aims: To evaluate the efficacy, safety, and cost-effectiveness of baloxavir marboxil tablets versus oseltamivir phosphate capsules for treatment of influenza from the health-care system perspective.
Materials and methods: Influenza patients were assigned to receive baloxavir marboxil (baloxavir group) or oseltamivir phosphate (oseltamivir group) and followed prospectively. Clinical outcomes, adverse events, and direct medical costs during treatment were collected. A cost-effectiveness analysis was performed from the health-care system perspective. Incremental cost-effectiveness ratios (ICERs) were calculated using 48-hour and 5-day recovery rates as effectiveness measures. Sensitivity analyses assessed drivers of results.
Results: A total of 102 cases treated with baloxavir and 81 cases treated with oseltamivir were analyzed. There were no significant differences between groups in 5-day overall effectiveness (p = 0.111) or 5-day defervescence rate (p = 0.115). The baloxavir group showed significantly higher 48-hour effectiveness (p < 0.001), 48-hour recovery rate (p < 0.001), 48-hour defervescence rate (p < 0.001), and 5-day recovery rate (p = 0.023) compared with the oseltamivir group. Adverse event incidence was significantly lower in the baloxavir group (p < 0.001). Sensitivity analysis identified the antiviral agent as a significant driver of 48-hour effectiveness (p = 0.004), 48-hour recovery (p = 0.013), and 48-hour defervescence (p = 0.008). Results remained robust across analyses. Total outpatient and drug costs were significantly higher in the baloxavir group (both p < 0.001). Using 48-hour recovery and 5-day recovery as effectiveness endpoints, the ICERs for baloxavir versus oseltamivir were ¥92.23 and ¥794.29 per additional recovered patient, respectively.
Conclusion: Baloxavir marboxil is superior to oseltamivir in efficacy, safety, and cost-effectiveness for influenza.

Author Details

Authors

Departments

  • 1 Department of Pharmacy, the First People’s Hospital of Lianyungang, Lianyungang Jiangsu,
  • 2 Department of Pharmacy, the Affiliated Hospital of Xuzhou Medical University, and
  • 3 Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou Jiangsu, China

Address

Dr. Daoli Jiang
Department of Pharmacy
the Affiliated Hospital of Xuzhou Medical University
Xuzhou Jiangsu, 221006, China
and
Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy
Xuzhou Medical University
Xuzhou Jiangsu, 221004, China
Email: [email protected]

Log in for Subscribers

Citation

Yongli Gu, Daoli Jiang. Baloxavir marboxil versus oseltamivir phosphate: Efficacy, safety, and economics in patients with influenza
. Int J Clin Pharmacol Ther. 2026; 64: 646-657. doi: 10.5414/CP204995. Pubmed: https://pubmed.ncbi.nlm.nih.gov/42788288/; PMID: 42788288.

###article_not_exists_msg###

Shopping Overview

Shopping Overview
Type Qtty Discount VAT Price
Your basket is empty
View Cart